Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04499924
Title Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Seagen Inc.
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Paclitaxel + Ramucirumab + Trastuzumab + Tucatinib

Paclitaxel + Ramucirumab + Tucatinib

Paclitaxel + Ramucirumab

Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.